Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy

British Journal of Cancer

Volumn 104, Issue 4, 2011, Pages 559-563

  Yun, J ^a   Kim, K H ^a   Kang, E S ^a   Gwak, G Y ^a   Choi, M S ^a   Lee, J E ^a   Nam, S J ^a   Yang, J H ^a   Park, Y H ^a   Ahn, J S ^a   Im, Y H ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

adjuvant chemotherapy; breast cancer; doxorubicin; hepatitis B reactivation

Indexed keywords

ADEFOVIR DIPIVOXIL; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PACLITAXEL;

ADD ON THERAPY; ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; VIRUS REACTIVATION;

ADULT; AGED; ALGORITHMS; ANTHRACYCLINES; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; BREAST NEOPLASMS; CARCINOMA; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HEPATITIS B; HUMANS; INCIDENCE; LAMIVUDINE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES;

EID: 79951675971     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.4     Document Type: Article

References (25)

1. Artz AS, Somerfield MR, Feld JJ, Giusti AF, Kramer BS, Sabichi AL, Zon RT, Wong SL (2010) American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 28(19): 3199-3202
2. Bennett JM, Muss HB, Doroshow JH, Wolff S, Krementz ET, Cartwright K, Dukart G, Reisman A, Schoch I (1988) A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 6(10): 1611-1620 (Pubitemid 19092398)
3. Chae HB, Kim JH, Kim JK, Yim HJ (2009) Current status of liver disease in Korea: Hepatitis B. Korean J Hepatol (Suppl 6): S13-S24
4. Crown J, Dieras V, Kaufmann M, von Minckwitz G, Kaye S, Leonard R, Marty M, Misset JL, Osterwalder B, Piccart M (2002) Chemotherapy for metastatic breast cancer-report of a European expert panel. Lancet Oncol 3(12): 719-727 (Pubitemid 35446740)
5. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31510 women. J Clin Oncol 16(10): 3439-3460 (Pubitemid 28481644)
6. Green JA, Slater AJ, Campbell IR, Kelly V (1996) Advanced breast cancer: a randomized study of doxorubicin or mitoxantrone in combination with cyclophosphamide and vincristine. Breast Cancer Res Treat 39(2): 155-163 (Pubitemid 26283199)
7. Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D (1989) Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7(5): 560-571 (Pubitemid 19126791)
8. Idilman R, Arat M, Soydan E, Toruner M, Soykan I, Akbulut H, Arslan O, Ozcan M, Turkyilmaz AR, Bozdayi M, Karayalcin S, Van Thiel DH, Ozden A, Beksac M, Akan H (2004) Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 11(2): 141-147 (Pubitemid 38365765)
9. Khokhar OS, Farhadi A, McGrail L, Lewis JH (2009) Oncologists and hepatitis B: a survey to determine current level of awareness and practice of antiviral prophylaxis to prevent reactivation. Chemotherapy 55(2): 69-75
10. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF (1998) A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339(2): 61-68 (Pubitemid 28304879)
11. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, Cheung M, Zhang HY, Lie A, Ngan R, Liang R (2003) Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125(6): 1742-1749 (Pubitemid 37500439)
12. Lee DH, Kim JH, Nam JJ, Kim HR, Shin HR (2002) Epidemiological findings of hepatitis B infection based on 1998 National Health and Nutrition Survey in Korea. J Korean Med Sci 17(4): 457-462
13. Lee GW, Ryu MH, Lee JL, Oh S, Kim E, Lee JH, Kim SB, Kim SW, Suh C, Lee KH, Kim WK, Lee JS, Kang YK (2003) The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci 18(6): 849-854 (Pubitemid 38072936)
14. Lee WM (1997) Hepatitis B virus infection. N Engl J Med 337(24): 1733-1745 (Pubitemid 27527771)
15. Lok AS, Lai CL, Wu PC, Wong VC, Yeoh EK, Lin HJ (1987) Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol 126(3): 492-499
16. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100(1): 182-188
17. Lok AS, McMahon BJ (2007) Chronic hepatitis B. Hepatology 45(2): 507-539 (Pubitemid 46374607)
18. Lok AS, McMahon BJ (2009) Chronic hepatitis B: update 2009. Hepatology 50(3): 661-662
19. Mindikoglu AL, Regev A, Schiff ER (2006) Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 4(9): 1076-1081 (Pubitemid 44311645)
20. Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22(4): 263-302 (Pubitemid 30213944)
21. Rossi G, Pelizzari A, Motta M, Puoti M (2001) Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 115(1): 58-62 (Pubitemid 32995093)
22. Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, Chan AT, Mok TS, Lee JJ, Leung TW, Zhong S, Johnson PJ (2004a) Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22(5): 927-934 (Pubitemid 41103605)
23. Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S, Johnson PJ (2003) Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 70(4): 553-561 (Pubitemid 36734719)
24. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62(3): 299-307
25. Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, Lam KC, Johnson PJ (2004b) Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90(7): 1306-1311 (Pubitemid 38586252)